Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply� and “GSK insider trading Form 4 transactions.�
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK plc disclosed that on 21 July 2025 it repurchased 504,228 ordinary shares (nominal 31¼ p) through Merrill Lynch International under its 4 June 2025 non-discretionary buy-back programme. Transaction prices ranged from 1,337p to 1,357p with a VWAP of 1,344.38p, representing a cash outlay of roughly £6.8 million. Since programme inception, 15,187,312 shares have been bought back.
All shares are held in treasury, increasing the treasury balance to 233,321,695 shares, now 5.72 % of total voting rights. Issued share capital (excluding treasury) stands at 4,082,062,585 shares, which becomes the denominator for FCA DTR calculations. No earnings, guidance or other financial data were included.
On 18 Jul 2025, GSK plc bought back 505,771 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its previously announced non-discretionary buy-back programme.
The shares were purchased between 1,319.0 p and 1,360.5 p, with a volume-weighted average price of 1,344.42 p. Since the programme commenced on 4 Jun 2025, GSK has repurchased 14,683,084 shares.
Following this latest transaction, the company now holds 232,817,467 shares in treasury, representing 5.70 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,082,566,813, which investors should use as the denominator when assessing disclosure thresholds under the FCA’s DTR rules.
The filing contains no new earnings or guidance; it solely updates the market on the progress of GSK’s authorised share-repurchase programme.
On 15 Jul 2025, GSK plc repurchased 487,387 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its on-market buy-back. The shares were bought at 1,401.50-1,493.50 p, giving a volume-weighted average price of 1,423.89 p and an estimated cash cost of £6.9 million.
Since the non-discretionary programme began on 4 Jun 2025, GSK has acquired 13,210,173 shares. The company now holds 231,344,556 shares in treasury, equivalent to 5.66 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,084,039,501, which is the denominator investors should use for disclosure calculations under the FCA’s DTR rules.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
